Finch Therapeutics Group, Inc. – NASDAQ:FNCH
Finch Therapeutics Group stock price today
$12.69
+1.82
+16.74%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 13 hours
Finch Therapeutics Group stock price monthly change
+660.14%
month
Finch Therapeutics Group stock price quarterly change
+660.14%
quarter
Finch Therapeutics Group stock price yearly change
+207.06%
year
Finch Therapeutics Group key metrics
Market Cap | 16.29M |
Enterprise value | N/A |
P/E | -0.16 |
EV/Sales | -9.66 |
EV/EBITDA | 0.09 |
Price/Sales | 11.49 |
Price/Book | 0.18 |
PEG ratio | N/A |
EPS | -10.14 |
Revenue | N/A |
EBITDA | -23.26M |
Income | -16.28M |
Revenue Q/Q | -100% |
Revenue Y/Y | 363.35% |
Profit margin | -10273.67% |
Oper. margin | -9046.45% |
Gross margin | 0% |
EBIT margin | -9046.45% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeFinch Therapeutics Group stock price history
Finch Therapeutics Group stock forecast
Finch Therapeutics Group financial statements
| Jun 2023 | 0 | -6.95M | |
|---|---|---|---|
| Sep 2023 | 0 | -2.41M | |
| Dec 2023 | 2.84M | -3.04M | -106.89% |
| Mar 2024 | 0 | -3.87M |
| 2025 | 88.5M | -17.32M | -19.58% |
|---|---|---|---|
| 2026 | 345.4M | 85.68M | 24.81% |
Analysts Price target
Financials & Ratios estimates
| 2023-08-10 | -4.51 | -4.33 |
|---|
| Jun 2023 | 66857000 | 38.96M | 58.28% |
|---|---|---|---|
| Sep 2023 | 59493000 | 33.68M | 56.61% |
| Dec 2023 | 70997000 | 48.11M | 67.76% |
| Mar 2024 | 50092000 | 31.05M | 61.99% |
| Jun 2023 | -9.15M | 1.27M | 4K |
|---|---|---|---|
| Sep 2023 | -5.26M | 20K | 0 |
| Dec 2023 | -3.70M | 51K | 0 |
| Mar 2024 | -4.36M | 0 | 0 |
Finch Therapeutics Group alternative data
| Aug 2023 | 18 |
|---|---|
| Sep 2023 | 18 |
| Oct 2023 | 18 |
| Nov 2023 | 18 |
| Dec 2023 | 18 |
| Jan 2024 | 18 |
| Feb 2024 | 18 |
| Mar 2024 | 18 |
| Apr 2024 | 18 |
| May 2024 | 1 |
| Jun 2024 | 1 |
| Jul 2024 | 1 |
Finch Therapeutics Group other data
7.43%
-12.65%
of FNCH is owned by hedge funds
15
-21
3.54M
-6.04M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 5010 | 0 |
| Nov 2023 | 0 | 1470 |
| Mar 2024 | 0 | 8242 |
| Insider | Compensation |
|---|---|
| Dr. Mark Burnham Smith (1987) Chief Executive Officer & Director | $644,520 |
| Mr. Gregory D. Perry (1960) Chief Financial Officer | $581,310 |
Finch Therapeutics: Why This Finch Could Fly - An Asymmetric Risk/Reward Opportunity
The Clock Is Ticking For Seres Therapeutics: I'm Not Afraid
Seres Gets Closer To Good Times
Seres Therapeutics: What The Market Is Missing
Seres Therapeutics: The Pipeline Is The Problem
Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus
Finch Therapeutics: Gut Instinct Says Buy
-
What's the price of Finch Therapeutics Group stock today?
One share of Finch Therapeutics Group stock can currently be purchased for approximately $12.69.
-
When is Finch Therapeutics Group's next earnings date?
Unfortunately, Finch Therapeutics Group's (FNCH) next earnings date is currently unknown.
-
Does Finch Therapeutics Group pay dividends?
No, Finch Therapeutics Group does not pay dividends.
-
How much money does Finch Therapeutics Group make?
Finch Therapeutics Group has a market capitalization of 16.29M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 87.57% to 107K US dollars. Finch Therapeutics Group made a loss 74.75M US dollars in net income (profit) last year or -$4.33 on an earnings per share basis.
-
What is Finch Therapeutics Group's stock symbol?
Finch Therapeutics Group, Inc. is traded on the NASDAQ under the ticker symbol "FNCH".
-
What is Finch Therapeutics Group's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Finch Therapeutics Group?
Shares of Finch Therapeutics Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Finch Therapeutics Group's key executives?
Finch Therapeutics Group's management team includes the following people:
- Dr. Mark Burnham Smith Chief Executive Officer & Director(age: 38, pay: $644,520)
- Mr. Gregory D. Perry Chief Financial Officer(age: 65, pay: $581,310)
-
How many employees does Finch Therapeutics Group have?
As Jul 2024, Finch Therapeutics Group employs 1 workers, which is 94% less then previous quarter.
-
When Finch Therapeutics Group went public?
Finch Therapeutics Group, Inc. is publicly traded company for more then 4 years since IPO on 19 Mar 2021.
-
What is Finch Therapeutics Group's official website?
The official website for Finch Therapeutics Group is finchtherapeutics.com.
-
Where are Finch Therapeutics Group's headquarters?
Finch Therapeutics Group is headquartered at 200 Inner Belt Road, Somerville, MA.
-
How can i contact Finch Therapeutics Group?
Finch Therapeutics Group's mailing address is 200 Inner Belt Road, Somerville, MA and company can be reached via phone at +61 72296499.
Finch Therapeutics Group company profile:
Finch Therapeutics Group, Inc.
finchtherapeutics.comExchange:
NASDAQ
Full time employees:
1
Industry:
Biotechnology
Sector:
Healthcare
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
200 Inner Belt Road
Somerville, MA 02143
Somerville, MA 02143
CIK: 0001733257
ISIN: US31773D2009
CUSIP: 31773D101
